rheumatology

News in Brief 12-02-21: QoL measures for Giant Cell Arteritis; New indication for guselkumab; Worst packaging offenders for arthritis patients named

Aussie rheums explore patient outcomes for GCA A core set of patient reported outcome measures (PROM) for patients undergoing treatment for Giant Cell Arteritis (GCA) is being developed by Australian and UK clinicians. The 40-item draft questionnaire, the first disease-specific PROM to explore the impact of GCA and its treatment on peoples’ health related quality ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic